CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. The CCR2... The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis.
- Mechanism
- Curator reviewed
Mechanism of action indicates that CCX915 selectively inhibits CCR2-mediated migration of inflammatory white blood cells, but do not inhibit migration mediated by other chemokine receptors, even when administered at high concentrations. Based on the high degree of target specificity observed, CCX915 has the potential to avoid the undesirable side effects of traditional immunosuppressive therapies used in MS and other autoimmune disease indications.
- Primary indication
- Investigated for use/treatment in multiple sclerosis and neurologic disorders.Curator reviewed
- Code names
- CCX915
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with CCX915, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account